Navigation Links
Research Shows 10-15% Will Need Periodontal Treatment – Act Now, Warn Eludril and Elgydium
Date:4/23/2013

Bournemouth, Dorset (PRWEB) April 23, 2013

New research which shows that 10 to 15 per cent of adults will develop periodontitis has prompted a warning from the manufacturers of Elgydium toothpaste and Eludril mouthwash.

The research – published recently in the National Library of Medicine – highlights the dangers of ignoring the early signs of gum disease (gingivitis).

If left unchecked, gingivitis can worsen and develop into periodontitis, an advanced form of gum disease which can attack bone as well as soft tissue.

Gum disease has far reaching consequences with well documented associations with more serious conditions such as cardiac and respiratory problems, diabetes, some cancers and osteoporosis – as well as dementia and premature birth.

“Gingivitis is serious enough but periodontitis is even more serious and can do lasting damage to the bones of the mouth as well as the gums,” said a spokesperson for Eludril and Elgydium.

“And yet there is no need to suffer with a painful gum condition. Gingivitis and periodontitis are both avoidable. Gum disease is easy to identify and simple to treat if caught early.

“Even if people miss the initial warning signs such as the gum swelling around the teeth, there are other indications which are hard to ignore.”

Blood on the gums can be caused by brushing teeth too vigorously but all too often it is a clear indication of gingivitis.

Gum recession – with or without bleeding – is another serious warning sign that should not be ignored, although this too can be caused by over-enthusiastic or careless brushing.

Regular checks by dental professionals are important in diagnosing the symptoms of gingivitis early – before the condition worsens and develops into periodontitis.

For decades, dentists and hygienists all over the world have recommended chlorhexidine (an important ingredient in both Elgydium and Eludril) as the gold standard treatment for gum disease.

Not only does chlorhexidine treat gingivitis and periodontitis but regular brushing with one of the Elgydium range of antibacterial toothpastes can help to prevent them.

Elgydium is strong enough to kill the bacteria that cause gum disease but can be used daily as part of a normal oral health regime.

Eludril gingivitis mouthwash should be used two or three times daily while symptoms persist. The recommended dosage of Eludril is 10 to 15 ml, diluted with warm water in the measuring cup provided. It is a quick and simple treatment for when gum disease is detected.

Eludril can also be used to disinfect dentures, using a one-in-three dilution with water. The dentures should be cleansed as normal then soaked in the Eludril dilution for around 60 minutes.

For further details about treating periodontitis with Eludril and Elgydium, please contact Chloe Rogers at Ceuta Healthcare on +44 (0)844 243 6661.

-Ends-

Notes For Editors

Eludril and Elgydium are represented in the UK by:

Ceuta Healthcare Ltd
Hill House
41 Richmond Hill
Bournemouth
Dorset
BH2 6HS
Tel: +44 (0)844 243 6661

Eludril Mouthwash is an antibacterial and analgesic solution which can be used to manage a number of oral health problems.

Its main use is to treat and prevent dental plaque formation and gum disease (gingivitis, also known as periodontitis) by preventing the build-up of bacteria.

Eludril Mouthwash can also be used to maintain oral hygiene in situations where tooth brushing is difficult, for instance, following oral surgery or in physically or mentally handicapped patients.

Eludril can also be used as a disinfectant for the cleansing of removable dentures and in the management of common mouth ulcers and oral candidiasis infections (fungus infections).

Elgydium Anti-Plaque toothpaste is specially formulated for sensitive gums and helps to prevent dental plaque and tartar build-up, the major causes of tooth decay and gum disease.

Elgydium Whitening, Sensitive and Decay Protection are also available as part of the Elgydium range of toothpastes.

Read the full story at http://www.prweb.com/releases/periodontal/treatment/prweb10646875.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Seena Magowitz Foundation donates $500,000 for TGen pancreatic cancer research
2. Researchers identify new pathway, enhancing tamoxifen to tame aggressive breast cancer
3. New research project aims to improve cancer therapies using type I interferons
4. Should kids sit less or move more? CHEO Research answers
5. The Melanoma Research Alliance Foundation supports CNIO research
6. Deficiency in p53 anti-tumor protein delays DNA repair after radiation, Moffitt researchers say
7. Latest research shows 2 items are key to decrease symptoms and prolong survival for LMC patients
8. Wayne State researchers seek calcium channels to target cancer tumors
9. Medical Device Market: Peru & Philippines New Market Research Report Available At Researchmoz.us
10. Toothpaste and Toothbrush Manufacturing in China Industry Research Report – Now Available from IBISWorld
11. Medical Robotic Systems Market - New Market Research Report Published by Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: